EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113

Mao Okada iD, Eiichiro Suzuki, Chigusa Morizane iD, Gakuto Ogawa, Yusuke Sano iD, Hiroshi Imaoka iD, Satoshi Kobayashi, Masafumi Ikeda, Naohiro Okano iD, Haruo Miwa, Akiko Todaka iD, Satoshi Shimizu iD und 10 weitere

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf035 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Mao Okada und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Liver Cirrhosis, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center Research and Development Funds, Japan Agency for Medical Research and Development, Clinical Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The JCOG1113, a multicenter, randomized phase III trial in patients with advanced/recurrent biliary tract cancer showed the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin. Although liver cirrhosis (LC) is a known risk factor for intrahepatic cholangiocarcinoma (ICC), few reports focus on the efficacy and safety of chemotherapy in ICC patients with LC.

Methods

We performed a subgroup analysis of ICC patients enrolled in the JCOG1113. The presence or absence of LC was evaluated based on clinical factors such as radiographic findings, medical history, laboratory data, and physical examination at enrollment. We evaluated differences in the safety and efficacy of chemotherapy according to the presence or absence of clinically diagnosed LC.

Results

Of the 94 eligible patients with ICC, 10 were clinically diagnosed with LC. In the non-LC/clinically diagnosed LC group, grade 3 or 4 neutropenia, anemia, decreased platelet count, and non-hematological adverse events were observed in 51.2%/60%, 15.5%/0%, 11.9%/40%, and 38.1%/30% patients. The median overall survival was 13.7 months in the non-LC group and 19.0 months in the clinically diagnosed LC group (hazard ratio [HR]: 0.969, 95% confidence interval [CI]: 0.482–1.948). The median progression-free survival was 5.9 months in the non-LC group and 7.1 months in the clinically diagnosed LC group (HR, 0.995; 95% CI, 0.513–1.929).

Conclusion

The results of this study indicated that eligible ICC patients with clinically diagnosed LC, as determined by clinical and CT imaging findings, did not exhibit any apparent safety or efficacy disadvantage compared to those without LC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsLiver CirrhosisAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedGemcitabineDeoxycytidineCisplatinTegafurOxonic AcidAdultDrug Combinations

Stichwörter der Autor:innen

chemotherapyintrahepatic cholangiocarcinomaliver cirrhosis

Substanzen

GemcitabineDeoxycytidineCisplatinTegafurOxonic AcidDrug CombinationsS 1 (combination)

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Courses of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.
  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
  • Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.

ORCID-Profile: Mao Okada, Chigusa Morizane, Yusuke Sano, Hiroshi Imaoka, Naohiro Okano, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno

Förderung

  • National Cancer Center Research and Development Funds
  • Japan Agency for Medical Research and Development
  • Clinical Cancer Research
  • Ministry of Health, Labour, and Welfare of Japan

Zitieren

APA

Okada, M., Suzuki, E., Morizane, C., Ogawa, G., Sano, Y., Imaoka, H., Kobayashi, S., Ikeda, M., Okano, N., Miwa, H., Todaka, A., Shimizu, S., Mizuno, N., Satoi, S., Sano, K., Tobimatsu, K., Katanuma, A., Masutomi, K., Okusaka, T., …, & members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG) (2025). Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf035

Vancouver

Okada M, Suzuki E, Morizane C, Ogawa G, Sano Y, Imaoka H, et al. Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf035

BibTeX
@article{Okada2025,
  author = {Okada, Mao and Suzuki, Eiichiro and Morizane, Chigusa and Ogawa, Gakuto and Sano, Yusuke and Imaoka, Hiroshi and Kobayashi, Satoshi and Ikeda, Masafumi and Okano, Naohiro and Miwa, Haruo and Todaka, Akiko and Shimizu, Satoshi and Mizuno, Nobumasa and Satoi, Sohei and Sano, Keiji and Tobimatsu, Kazutoshi and Katanuma, Akio and Masutomi, Kenkichi and Okusaka, Takuji and Ozaka, Masato and Ueno, Makoto and members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG), members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG)},
  title = {Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf035}
}
Kostenlos starten →